To demonstrate tumor specific delivery of Pep1L, a novel peptide discovered to target IL13RA2, we radiolabeled it with positron emitting Cu-64 and demonstrated its ability in vitro and in vivo to target IL13RA2-expressing human GBMs. Here, IL13RA2 is linked to neoplasm.